Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1958 1
1959 1
1960 1
1962 2
1965 1
1967 1
1969 4
1970 5
1971 3
1972 2
1973 1
1974 5
1975 6
1976 6
1978 5
1979 6
1980 2
1981 4
1982 3
1983 8
1984 6
1985 6
1986 1
1987 3
1989 3
1990 5
1992 5
1993 5
1994 6
1995 6
1996 12
1997 4
1998 13
1999 12
2000 11
2001 15
2002 14
2003 6
2004 9
2005 9
2006 3
2007 7
2008 15
2009 16
2010 12
2011 25
2012 15
2013 13
2014 22
2015 17
2016 27
2017 28
2018 21
2019 27
2020 41
2021 54
2022 39
2023 36
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

580 results

Results by year

Filters applied: . Clear all
Page 1
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. Nilsson MB, et al. Among authors: gibbons dl. Cancer Cell. 2023 Feb 13;41(2):340-355.e6. doi: 10.1016/j.ccell.2023.01.007. Cancer Cell. 2023. PMID: 36787696 Free PMC article.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Negrao MV, et al. Among authors: gibbons dl. Cancer Discov. 2023 Jul 7;13(7):1556-1571. doi: 10.1158/2159-8290.CD-22-1420. Cancer Discov. 2023. PMID: 37068173
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF. Ravi A, et al. Among authors: gibbons dl. Nat Genet. 2023 May;55(5):807-819. doi: 10.1038/s41588-023-01355-5. Epub 2023 Apr 6. Nat Genet. 2023. PMID: 37024582 Free PMC article.
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G Jr, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Cascone T, et al. Among authors: gibbons dl. Nat Med. 2023 Mar;29(3):593-604. doi: 10.1038/s41591-022-02189-0. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928818 Free PMC article. Clinical Trial.
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer.
Cascone T, Fradette J, Pradhan M, Gibbons DL. Cascone T, et al. Among authors: gibbons dl. Cold Spring Harb Perspect Med. 2022 May 27;12(5):a037895. doi: 10.1101/cshperspect.a037895. Cold Spring Harb Perspect Med. 2022. PMID: 34580079 Free PMC article. Review.
The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.
Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu D. Li H, et al. Among authors: gibbons dl. Cancer Cell. 2022 Jan 10;40(1):36-52.e9. doi: 10.1016/j.ccell.2021.11.002. Epub 2021 Nov 24. Cancer Cell. 2022. PMID: 34822775 Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G Jr, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Cascone T, et al. Among authors: gibbons dl. Nat Med. 2021 Mar;27(3):504-514. doi: 10.1038/s41591-020-01224-2. Epub 2021 Feb 18. Nat Med. 2021. PMID: 33603241 Free PMC article. Clinical Trial.
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, Fan Y, Yang Y, Wang J, Glisson BS, Wistuba II, Sage J, Heymach JV, Gibbons DL, Byers LA. Sen T, et al. Among authors: gibbons dl. Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18. Cancer Discov. 2019. PMID: 30777870 Free PMC article.
580 results